@ilcpress Signing off from #ILC2016 in beautiful Barça and already looking forward to #ILC2017 in one of my favorites cities: Amsterdam
0
0
0
0
#ILC2016
Latest posts tagged with #ILC2016 on Bluesky
Trending
Posts tagged #ILC2016
@EASLedu Very alarming data from #ILC2016 high rate of HCC in 6 mos-1y after #HCV cure. F3/F4 fibrosis DAA cures require close surveillance
1
0
0
0
@EASLnews @PSCPartners @PSCPatientsEur finally some momentum for #PSC with norUDCA holding promise and OCA trials underway #ILC2016
0
0
0
0
@ILCpress liver cancer: not much new treatment but PD-1 immune checkpoint inhibitors hold promise for "hypermutated" tumors #ILC2016
0
0
0
0
@ILCpress #HCV news at #ILC2016 include prevalent viral chimeras 2K/1b originating from former Soviet Union. Need core sequencing to detect
0
0
0
0
@EASLedu fatty liver main focus of future meetings. Main take home here is only endpoint that truly matters is fibrosis #ILC2016
1
0
0
0
@EASLedu momentum shift clearly towards #HBV and even #HEV cure but targets remain to be defined. Innate immunity, PD-1, entry? #ILC2016
0
0
0
0
@EASLnews @fixhepc strategy more widespread with apparently over 40k in India alone having already received #HCV generics #ILC2016
0
0
0
0
@fixhepc generic drug strategy may be one way to expand access #HCV access. Undoubtedly emotional highlight of #ILC2016
0
0
0
0
@EASLnews #hcv therapies are approaching "cure all" point. Minor refinements ahead. Major issue worldwide is access. #ILC2016
0
0
0
0
@EASLnews as #ILC2016 winds down a few take home points related to #hcv liver cancer #hbv fatty liver and cholestatic liver disease
0
0
0
0
@EASLedu @JHepatology editors not planning on starting other journals focused on basic or clinical science at the moment #ILC2016
0
0
0
0
@ILCAnews upcoming @JHepatology publication highlights #HEV tissue tropism and shows that the virus can be transmitted via urine #ILC2016
0
0
0
0
@EASLedu Prof. Berg: PAGE-B score predicts risk of hepatocellular carcinomas based on age, gender and platelet count in #HBV #ILC2016
0
0
0
0
@ILCpress Prof. Bataller: #EASL #EASO #EASD joint guidelines on management of NAFLD now available in @JHepatology #ILC2016
0
0
0
0
@ILCpress Prof. Bataller: only 3% of @JHepatology submissions related to alcoholic liver disease. Need to foster more interest #ILC2016
0
0
0
0
@EASLedu Last but not least day of #ILC2016 currently at the best of @JHepatology review chaired by @RajivJalan1
0
0
0
0
0
0
0
0
@ILCpress Prof. kudo: Hepatic artery chemo infusion plus #sorafenib RCT does not increase overall survival. Potentially more AEs. #ILC2016
0
0
0
0
@EASLedu Freeman data @fixhepc met with rapturous applause. Quality control and legality questions raised #ILC2016
0
0
0
0
@EASLedu @ILCpress Dr. Freeman @fixhepc generic NMR vetted #HCV rx from China/Bangladesh/etc show similar cure to clinical trials #ILC2016
0
0
0
0
@PSCPartners @EASLedu @PSCPatientsEur norUDCA data promising. Good news for #PSC patients: a disease with no proven treatment #ILC2016
0
0
0
0
@EASLedu @PSCPartners norUDCA significantly reduced AlkPhos in #PSC patients though more so in those with lower baseline levels #ILC2016
0
0
0
0
@ILCpress Dr. Kwo: ABT-493/530 achieves 100% SVR4 in GT3 compensated cirrhotics #ILC2016
0
0
0
0
@ILCpress could claudin-1 humanized monoclonal antibodies as monotherapy cure #HCV? Colpitts and colleagues report #ILC2016
0
0
0
0
@EASLnews Dr. Kwo: mITT analysis shows 100% cure of #HCV GT3 in non cirrhotic patients with 8 weeks of ABT-493/ABT-530 #ILC2016
0
0
0
0
Recurrent & worrisome theme from #ILC2016 is high rate of early HCC dx within 6 mos after cure of #HCV #LB-506
0
0
0
0
@ILCpress Prof. Jalan: #alfapump vs. LVP. Higher creatinine, more SAEs and 10/30 with pump patients still required paracentesis. #ILC2016
0
0
0
0
@EASLedu Dr. Bansal: #sofosvuvir #ledipasvir cures 97% adolescents and is safe in #HCV infected naive and experienced adolescents #ILC2016
0
0
0
0
@ILCpress is hepatic "defatting" the answer? Dr. Alvarez-Sola presents data on hepatotropic Fibapo that reduces TG in animal model #ILC2016
0
0
0
0